FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to a pharmaceutical combination for treating a patient with type 1 or 2 diabetes, including (a) Gly(A21)-Arg(B31)-Arg(B32) human insulin or/and its pharmaceutically acceptable thereof at a concentration of 60 to 6000 nmol/ml, and (b) desPro36Exendin-4(1-39)-Lys6NH2 or/and pharmaceutically acceptable salt thereof at a concentration of 10 mcg/ml to 20 mg/ml. Group of inventions also relates to the use of said pharmaceutical combination for treating a patient with type 1 or 2 diabetes; kit for treating a patient with type 1 or 2 diabetes, comprising said pharmaceutical combination; pharmaceutical composition for treating a patient with type 1 or 2 diabetes.
EFFECT: group of inventions provides a synergistic effect of treatment of diabetes.
28 cl, 14 ex, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF INSULIN AND GLP-1 AGONIST | 2009 |
|
RU2532378C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
| INSULIN PREPARATION CONTAINING METHIONINE | 2010 |
|
RU2540485C2 |
| COMPOSITIONS OF LONG-ACTING INSULIN | 2011 |
|
RU2564104C2 |
| STABILISED COMPOUNDS OF EXENDIN-4 | 2003 |
|
RU2376314C2 |
| NOVEL INSULIN DERIVATIVES WITH STRONGLY SLOWED PROFILE TIME/ACTION | 2009 |
|
RU2529952C2 |
| COMPOSITIONS OF LONG-TERM ACTION INSULINS | 2015 |
|
RU2642662C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 AGONIST AND METHIONINE | 2010 |
|
RU2573995C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2593960C2 |
| NOVEL INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME/ACTION PROFILE | 2009 |
|
RU2524423C2 |
